| Literature DB >> 29547758 |
Mohammad Hadi Karbalaie Niya1, Hossein Keyvani2, Fahimeh Safarnezhad Tameshkel3, Mostafa Salehi-Vaziri4, Sedigheh Teaghinezhad-S5, Farah Bokharaei Salim6, Seyed Hamid Reza Monavari1, Davod Javanmard1.
Abstract
Human papillomavirus (HPV) is a common viral infection worldwide associated with a variety of cancers. The integration of the HPV genome in these patients causes chromosomal instability and triggers carcinogenesis. The aim of this study was to investigate the HPV-16 genome physical status in four major cancers related to HPV infection. Formalin-fixed paraffin-embedded blocks from our previous projects on head and neck, colorectal, penile, and cervical cancers were collected, and HPV-16-positive specimens were used for further analysis. The DNA extraction copy number of E2 and E7 genes was calculated by qualitative real-time PCR method. Serially diluted standards that were cloned in PUC57 plasmid were used. Standard curve and melting curve analysis was used for quantification. Of the 672 specimens studied, 76 (11.3%) were HPV-16 positive. We found that 35.6% (16/45) were integrated. Statistical analysis showed that there were significant correlations between integration of HPV-16 and cervical cancer end-stage carcinogenesis (P < .0001), episomal form, and ASCUS lesions (P = .045). Significant correlation in penile cancer patients was seen between the episomal form and high-grade cancer stage (P = .037). Integration is a major factor in the carcinogenesis mechanism of HPV and has different prevalence in various cancers with a higher rate in progression except in penile cancer.Entities:
Year: 2018 PMID: 29547758 PMCID: PMC5854915 DOI: 10.1016/j.tranon.2018.02.017
Source DB: PubMed Journal: Transl Oncol ISSN: 1936-5233 Impact factor: 4.243
Descriptive Summary of HPV Survey Studies (n=672)
| HNSCC | CrCa | PeCa | CxCa | |||||
|---|---|---|---|---|---|---|---|---|
| HPV16+ | Total | HPV16+ | Total | HPV16+ | Total | HPV16+ | Total | |
| Total (%) | 2 (1.3) | 156 (23.7) | 3 (4.5) | 66 (10) | 6 (54) | 11 | 65 (14.9) | 436 (66.2) |
| Men (%) | 2 (1.6) | 121 (77.6) | 2 (66.7) | 38 (57.6) | 6 () | 11 | 0 | 0 |
| Women (%) | 0 | 35 (22.4) | 1 (33.3) | 28 (42.4) | 0 | 0 | 65 (14.9) | 436 (100) |
| Mean age±SD | 65.5±12.6 | 60.5±12.6 | 64.3±13.2 | 59.3±14.4 | 35.0±5.5 | 35.8±5.7 | 38.4±13.6 | 35.3±10.1 |
| Range | 54-77 | 28-86 | 50-76 | 27-85 | 28-40 | 26-44 | 23-62 | 18-73 |
| Other HPVs | - | - | - | - | - | - | 25 (38.5) | 198 (45.4) |
Co-infected with other HPVs. HNSCC, head and neck squamous cell carcinoma; CrCa, colorectal cancer; PeCa, penile cancer; CxCa, cervical cancer; SD, standard deviation.
Pathologic Characteristics of our HPV-16–Positive Cases (n=45)
| HNSCC (%) | CrCa (%) | PeCa (%) | CxCa (%) | |
|---|---|---|---|---|
| High grade | 1 (50) | 1 (33.3) | 2 (33.3) | - |
| Low grade | 1 (50) | 2 (66.7) | 4 (66.7) | - |
| ASCUS | - | - | - | 8 (23.5) |
| LSIL | - | - | - | 6 (17.6) |
| HSIL | - | - | - | 11 (32.3) |
| Cancerous | - | - | - | 9 (26.5) |
| Total | 2 (4.4) | 3 (6.7) | 6 (13.3) | 34 (75.6) |
ASCUS, atypical squamous cells of undetermined significance; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion.
Figure 1Frequency of HPV-16 genome status in our 45 cancerous patients. HNSCC, head and neck squamous cell carcinoma; CrCa, colorectal cancer; PeCa, penile cancer; CxCa, cervical cancer.
Demographic and Pathologic Genome Status of Our Included Patients (n=45)
| Genome Status | No (%) | Sex | Age Mean ± SD | Grade | Pathologic Feature | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| High | Low | ASCUS | LSIL | HSIL | Cancerous | |||||
| HNSCC | Integrated | 1 (50) | Man | 77 | 0 | 1 | - | - | - | - |
| Mixed | 1 (50) | Man | 54 | 1 | 0 | - | - | - | - | |
| CrCa | Episomal | 1 (33) | Man | 76 | 1 | 0 | - | - | - | - |
| Integrated | 1 (33) | Woman | 67 | 0 | 1 | - | - | - | - | |
| Mixed | 1 (33) | Man | 50 | 1 | 0 | - | - | - | - | |
| PeCa | Episomal | 3 (50) | Men | 32.0±6.9 | 3 | 0 | - | - | - | - |
| Integrated | 1 (17) | Man | 40 | 1 | 0 | - | - | - | - | |
| Mixed | 2 (33) | Men | 35.5±2.1 | 1 | 1 | - | - | - | - | |
| CxCa | Episomal | 7 (21) | Women | 30.7±3.4 | - | - | 4 | 2 | 0 | 1 |
| Integrated | 13 (38) | Women | 29.6±3.9 | - | - | 1 | 3 | 5 | 4 | |
| Mixed | 14 (41) | Women | 31.1±10.5 | - | - | 3 | 1 | 6 | 4 | |